HPV Vaccine: HHS Updates to 1 Dose Schedule & Expert Concerns

The childhood vaccine schedule has undergone a significant update, with the Department of Health and Human Services (HHS) recently announcing a reduction in the number of universally recommended vaccines from 17 to 11. While the Human Papillomavirus (HPV) vaccine remains a recommended immunization for all children at age 11 or 12, the new guidance suggests that a single dose may now be sufficient, a shift from previous recommendations of two or three doses. This change reflects evolving research demonstrating the effectiveness of a reduced dosage schedule.

From Three to One: A Changing Understanding of HPV Vaccine Dosing

When the HPV vaccine was first introduced, a three-dose regimen was standard practice. This evolved to a two-dose schedule in recent years as real-world data indicated comparable efficacy. Now, emerging research suggests that even a single dose could provide adequate protection. The World Health Organization, the Advisory Committee on Immunization Practices (ACIP), and the Centers for Disease Control and Prevention (CDC) have all indicated that two doses are generally sufficient for most young people. Although, the latest findings point towards the potential for a single dose to be equally effective.

The impetus for this potential change stems from the ESCUDDO trial, a landmark study published in the New England Journal of Medicine in December 2025. Researchers enrolled over 20,000 girls aged 12-16 in Costa Rica, beginning in 2017, and randomly assigned them to one of four groups. These groups received either one or two doses of Cervarix (protecting against HPV types 16 and 18, responsible for approximately 70% of cervical cancers) or Gardasil 9 (protecting against nine HPV types linked to cancer and genital warts). Cervarix is no longer available in the United States, but remains in use in other countries.

The results were striking: all four groups demonstrated over 97% effectiveness. The study concluded that a single dose of either vaccine was as effective as two doses in protecting against HPV types 16 and 18. Gardasil 9, the only HPV vaccine currently available in the U.S., offers protection against these and seven additional HPV types associated with genital warts and cancers of the penis, vulva, anus, and throat. A similar randomized trial conducted in Kenya yielded comparable results, showing 98% effectiveness with a single dose of either vaccine against HPV 16 and 18.

Implications for Vaccine Uptake and Global Health

The potential shift to a single-dose HPV vaccine schedule could significantly improve vaccination rates. Reducing the number of required doses eliminates logistical barriers, such as the necessitate for multiple appointments, transportation costs, and time off from work or school. This simplification could be particularly impactful in low-resource countries, making large-scale vaccination campaigns more feasible and affordable. Increased vaccine uptake is crucial, as HPV infection is incredibly common; the CDC estimates that most sexually active people will contract HPV at some point in their lives.

A Note of Caution: AAP Recommendations and Transparency Concerns

Despite the promising research, the American Academy of Pediatrics (AAP) has not yet altered its recommendations. This discrepancy has raised concerns about potential confusion among healthcare providers and parents, as many pediatricians rely on AAP guidance for their vaccination protocols.

the HHS decision to modify the vaccine schedule was made without the typical advisory committee review process and public comment period. Traditionally, changes to vaccination schedules are deliberated by an advisory committee, allowing for public input before the CDC finalizes any new guidance. This lack of transparency has prompted criticism from some experts, who emphasize the importance of a collaborative and open decision-making process.

Understanding the HPV Vaccine and its Targets

The HPV vaccine works best when administered *before* any exposure to the virus. It doesn’t treat existing HPV infections or related diseases, but rather prevents new infections. HPV is a group of more than 200 related viruses, some of which can cause six types of cancer: cervical, anal, oropharyngeal (back of the throat, including base of the tongue and tonsils), vaginal, vulvar, and penile. It’s important to remember that HPV is not solely a sexually transmitted infection; it can also be spread through skin-to-skin contact.

What’s Next: Ongoing Evaluation and Pediatrician Guidance

Given the AAP’s continued adherence to the two-dose schedule and the concerns surrounding the HHS decision-making process, experts recommend that parents consult with their pediatrician to determine the most appropriate vaccination plan for their children. Pediatricians can provide personalized guidance based on individual health factors and the latest available evidence. The CDC continues to monitor the impact of the new guidance and will likely revisit its recommendations as more data develop into available. Ongoing surveillance and research will be crucial in evaluating the long-term effectiveness of a single-dose HPV vaccine schedule and ensuring optimal protection against HPV-related cancers and diseases.

The current CDC recommendations state that HPV vaccination is recommended for everyone through age 26 if they weren’t adequately vaccinated when younger. While vaccination is not generally recommended for individuals over 26, some adults aged 27 through 45 may choose to get vaccinated after discussing it with their clinician, particularly if they were not previously vaccinated.